DKSH Stock Analysis: DKSH Holding | SW
Consulting Services | SW, Switzerland | Market Cap: 4.214m CHF | 12M Return: 16% | CH0126673539 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.17M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DKSH Holding AG is a Zurich-based market expansion services provider specializing in the Asia-Pacific region. The company facilitates the entire value chain for clients, including sourcing, marketing, distribution, and logistics across four primary segments: Healthcare, Consumer Goods, Performance Materials, and Technology. By managing regulatory compliance and complex supply chains, DKSH acts as a critical intermediary for Western brands seeking to penetrate fragmented Asian markets.
The business model relies on capillary distribution, a system where the provider manages deep networks of small-scale retailers and local healthcare providers that are otherwise difficult for multinational corporations to access directly. In the industrial sector, this model reduces the capital expenditure requirements for manufacturers by outsourcing the technical sales and after-sales support of precision machinery and specialty chemicals. Detailed fundamental metrics for this business model are available on ValueRay for further analysis.
Operating as a diversified service provider, DKSH mitigates regional volatility by balancing high-growth consumer products with stable healthcare distribution and industrial technology. The company’s long-standing presence in Thailand and Malaysia provides a defensive moat built on established local infrastructure and deep regulatory expertise.
- Healthcare segment revenue grows on rising pharmaceutical demand in Southeast Asia
- Consumer Goods margins face pressure from inflationary logistics and distribution costs
- Performance Materials specialty chemical sourcing expands through strategic bolt-on acquisitions
- Thai Baht and Swiss Franc volatility impacts reported earnings and competitiveness
| Net Income: 212.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.22 > 1.0 |
| NWC/Revenue: 10.39% < 20% (prev 9.17%; Δ 1.21% < -1%) |
| CFO/TA 0.06 > 3% & CFO 339.3m > Net Income 212.2m |
| Net Debt (506.8m) to EBITDA (456.4m): 1.11 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.0m) vs 12m ago -3.13% < -2% |
| Gross Margin: 6.08% > 18% (prev 9.40%; Δ -3.32% > 0.5%) |
| Asset Turnover: 201.5% > 50% (prev 207.6%; Δ -6.05% > 0%) |
| Interest Coverage Ratio: 9.40 > 6 (EBIT TTM 302.6m / Interest Expense TTM 32.2m) |
| A: 0.21 (Total Current Assets 4.16b - Total Current Liabilities 3.02b) / Total Assets 5.55b |
| B: 0.36 (Retained Earnings 2.02b / Total Assets 5.55b) |
| C: 0.06 (EBIT TTM 302.6m / Avg Total Assets 5.47b) |
| D: 0.45 (Book Value of Equity 1.71b / Total Liabilities 3.78b) |
| Altman-Z'' = 3.39 = A |
| DSRI: 1.29 (Receivables 2.26b/1.78b, Revenue 11.0b/11.2b) |
| GMI: 1.55 (GM 9.40% / 6.08%) |
| AQI: 1.00 (AQ_t 0.19 / AQ_t-1 0.19) |
| SGI: 0.99 (Revenue 11.0b / 11.2b) |
| TATA: -0.02 (NI 212.2m - CFO 339.3m) / TA 5.55b) |
| Beneish M = -2.30 (Cap -4..+1) = BBB |
As of August 30, 2026, the stock is trading at CHF 65.80 with a total of 34,835 shares traded. Over the past week, the price has changed by -1.05%, over one month by -2.37%, over three months by +4.28% and over the past year by +16.02%.
Current recommended Stop Loss: 64.20 (which is 2.4% or 1.4 ATR below the current price).
DKSH Holding has no consensus analysts rating.
P/E Trailing = 19.9385
P/E Forward = 16.129
P/S = 0.3817
P/B = 2.5256
Revenue TTM = 11.0b CHF
EBIT TTM = 302.6m CHF
EBITDA TTM = 456.4m CHF
Long Term Debt = 468.2m CHF (from longTermDebt, last quarter)
Short Term Debt = 103.1m CHF (from shortTermDebt, last quarter)
Debt = 1.01b CHF (from shortLongTermDebtTotal, last quarter) + Leases 248.0m
Net Debt = 506.8m CHF (calculated: Debt 1.01b - CCE 503.7m)
Enterprise Value = 4.72b CHF (4.21b + Debt 1.01b - CCE 503.7m)
Interest Coverage Ratio = 9.40 (Ebit TTM 302.6m / Interest Expense TTM 32.2m)
EV/FCF = 15.30x (Enterprise Value 4.72b / FCF TTM 308.6m)
FCF Yield = 6.54% (FCF TTM 308.6m / Enterprise Value 4.72b)
FCF Margin = 2.80% (FCF TTM 308.6m / Revenue TTM 11.0b)
Net Margin = 1.93% (Net Income TTM 212.2m / Revenue TTM 11.0b)
Gross Margin = 6.08% ((Revenue TTM 11.0b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 6.52% (prev 5.65%)
Tobins Q-Ratio = 0.85 (Enterprise Value 4.72b / Total Assets 5.55b)
Interest Expense / Debt = 3.19% (Interest Expense 32.2m / Debt 1.01b)
Taxrate = 27.98% (85.4m / 305.2m)
NOPAT = 217.9m (EBIT 302.6m * (1 - 27.98%))
Current Ratio = 1.38 (Total Current Assets 4.16b / Total Current Liabilities 3.02b)
Debt / Equity = 0.59 (Debt 1.01b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 1.11 (Net Debt 506.8m / EBITDA 456.4m)
Debt / FCF = 1.64 (Net Debt 506.8m / FCF TTM 308.6m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.88% (Net Income 212.2m / Total Assets 5.55b)
RoE = 12.23% (Net Income TTM 212.2m / Total Stockholder Equity 1.73b)
RoCE = 13.74% (EBIT 302.6m / Capital Employed (Equity 1.73b + L.T.Debt 468.2m))
RoIC = 10.21% (NOPAT 217.9m / Invested Capital 2.13b)
WACC = 6.33% (E(4.21b)/V(5.22b) * Re(7.30%) + D(1.01b)/V(5.22b) * Rd(3.19%) * (1-Tc(0.28)))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -67.84 | Cagr: -1.51%
[DCF] Terminal Value 76.36% ; FCFF base≈300.2m ; Y1≈319.7m ; Y5≈381.1m
[DCF] Fair Price = 82.26 (EV 5.86b - Net Debt 506.8m = Equity 5.35b / Shares 65.0m; r=8.35% [WACC [floored]]; 5y FCF grow 7.34% → 2.50% )
EPS Correlation: -67.19 | EPS CAGR: -5.80% | SUE: N/A | # QB: 0
Revenue Correlation: 23.23 | Revenue CAGR: 0.22% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.68 | Chg30d=+0.84% | Revisions=-22% | GrowthEPS=+9.8% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=4.02 | Chg30d=+0.21% | Revisions=-12% | GrowthEPS=+9.1% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -21% (up=4, down=7)